Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dulaglutide vs Sitagliptin in T2DM (AWARD-5)
NCT00734474Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2008
- Primary completion
- Jun 2011
- Modality
- Fc-Fusion Proteins
- Countries
- 13
01
Overview
A Phase 3 trial of dulaglutide in type 2 diabetes mellitus (T2DM), sponsored by Eli Lilly and Company. Started Aug 2008; status: completed.
02
Drugs
dulaglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00734474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00734474.